| 1 |
33963708 | [Synergistic effect of polysaccharide from Trichoderma pseudokoningii and oxaliplatin on colorectal cancer cells in vitro]. | 2021 Apr 20 |
1 |
| 2 |
31727675 | Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial. | 2020 Feb 1 |
1 |
| 3 |
29378575 | Effects of Omegaven®, EPA, DHA and oxaliplatin on oesophageal adenocarcinoma cell lines growth, cytokine and cell signal biomarkers expression. | 2018 Jan 30 |
2 |
| 4 |
28459196 | Relationships of MMP-9, E-cadherin, and VEGF expression with clinicopathological features and response to chemosensitivity in gastric cancer. | 2017 May |
2 |
| 5 |
28621236 | Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial. | 2017 Jun |
1 |
| 6 |
25647613 | LoVo colon cancer cells resistant to oxaliplatin overexpress c-MET and VEGFR-1 and respond to VEGF with dephosphorylation of c-MET. | 2016 May |
3 |
| 7 |
27468218 | Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. | 2016 Jul 21 |
1 |
| 8 |
25707392 | Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy. | 2015 Oct |
3 |
| 9 |
26027741 | Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. | 2015 May |
1 |
| 10 |
27551256 | Update on Anti-Angiogenesis Therapy in Colorectal Cancer. | 2015 Dec |
1 |
| 11 |
24403498 | Targeted agents and oxaliplatin-containing regimens for the treatment of colon cancer. | 2014 Jan |
2 |
| 12 |
24701697 | Colorectal cancer: how emerging molecular understanding affects treatment decisions. | 2014 Feb |
1 |
| 13 |
23374220 | The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. | 2013 Feb 1 |
2 |
| 14 |
23786838 | Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells. | 2013 Sep |
1 |
| 15 |
23295255 | Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy. | 2012 |
1 |
| 16 |
23481572 | Low dose chemotherapeutic drugs without overt cytotoxic effects decrease the secretion of VEGF by cultured human tumor cells: a tentative relationship between drug type and tumor cell type response. | 2012-2013 |
1 |
| 17 |
20125120 | The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer. | 2011 Feb |
1 |
| 18 |
21791631 | Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. | 2011 Sep 1 |
2 |
| 19 |
20233520 | The synergistic effect of recombinant human endostatin (YH-16) combined with oxaliplatin on human colorectal carcinoma. | 2010 Jan-Feb |
2 |
| 20 |
19785749 | Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. | 2009 Sep 28 |
1 |
| 21 |
18778115 | Spotlight on bevacizumab in metastatic colorectal cancer. | 2008 |
2 |
| 22 |
18790786 | Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells. | 2008 Sep |
5 |
| 23 |
16101140 | Circulating vascular endothelial growth factor and interferon-gamma-inducible protein-10 levels in pancreatic cancer during chemotherapy. | 2005 Sep-Oct |
2 |
| 24 |
16270098 | Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting. | 2005 Nov |
1 |